Cargando…
In vitro antifungal activity of a novel topical triazole PC945 against emerging yeast Candida auris
OBJECTIVES: Management of Candida auris infection is difficult as this yeast exhibits resistance to different classes of antifungals, necessitating the development of new antifungals. The aim of this study was to investigate the susceptibility of C. auris to a novel antifungal triazole, PC945, optim...
Autores principales: | Rudramurthy, Shivaprakash M, Colley, Thomas, Abdolrasouli, Alireza, Ashman, Jed, Dhaliwal, Manpreet, Kaur, Harsimran, Armstrong-James, Darius, Strong, Pete, Rapeport, Garth, Schelenz, Silke, Ito, Kazuhiro, Chakrabarti, Arunaloke |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6753477/ https://www.ncbi.nlm.nih.gov/pubmed/31325309 http://dx.doi.org/10.1093/jac/dkz280 |
Ejemplares similares
-
Antifungal synergy of a topical triazole, PC945, with a systemic triazole against respiratory Aspergillus fumigatus infection
por: Colley, Thomas, et al.
Publicado: (2019) -
In Vivo Biomarker Analysis of the Effects of Intranasally Dosed PC945, a Novel Antifungal Triazole, on Aspergillus fumigatus Infection in Immunocompromised Mice
por: Kimura, Genki, et al.
Publicado: (2017) -
Safety and nonclinical and clinical pharmacokinetics of PC945, a novel inhaled triazole antifungal agent
por: Cass, Lindsey, et al.
Publicado: (2020) -
P005 Competitive fitness and trade-offs associated with azole resistance in Candida auris clinical isolates
por: Das, Sourav, et al.
Publicado: (2022) -
PC945, a Novel Inhaled Antifungal Agent, for the Treatment of Respiratory Fungal Infections
por: Murray, Alison, et al.
Publicado: (2020)